Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
San Francisco, United States
Countries of investment
  • USA
Investment stages
  • Pre-Seed
  • Seed
  • Series A
  • Series B
Industries
  • Health Tech
  • Biotechnology
  • AI
  • Data science
About
The Longevity Fund, founded by Laura Deming in 2011, focuses on investing in biotechnology and health tech companies that aim to develop drugs and technologies to extend healthy human lifespan. The fund has supported some of the pioneering companies in this space, helping them to IPO and bring drug candidates into clinical trials for agerelated diseases. They believe in the potential of unconventional and missiondriven founders to lead the field, advocating for a new generation of founders who can think differently about regulatory, scientific, fundraising, and companybuilding strategies. The Longevity Fund is now launching a new fund with a new name, with a continued commitment to advancing longevity science and medicine.
Min check size
$100K
Max check size
$1M
Fund size
NPS

Investment Thesis

The Longevity Fund aims to invest in companies developing drugs and technologies to extend healthy human lifespan.
Lead investor
Co Invest
Number of exits
Preferred contact method

The Longevity Fund Contacts Information

Primary contact

Secondary contact

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp